Literature DB >> 9919092

The preterm labor experience: a balancing act.

M A Coster-Schulz1, M C Mackey.   

Abstract

The purpose of the study was to identify how women described, interpreted, and managed their preterm labor experience. Ten married, middle-class women participated in an in-depth, tape-recorded interview in the hospital after preterm labor was stabilized; periodically over the telephone after discharge from the hospital; and in the hospital, home, or via telephone after birth, for a total of 31 interviews. Using qualitative data analysis techniques, the findings were conceptualized as five recursive stages: becoming aware that something was wrong and feeling unbalanced, making sense of the experience as they sought to understand why preterm labor occurred, trying different strategies to re-create a balance in their lives, addressing other life stressors that threatened restoring balance, and emerging from the preterm labor experience with added growth. An increased understanding of the preterm labor experience from the women's perspective can be helpful to health care professionals and others who support women during pregnancy.

Entities:  

Mesh:

Year:  1998        PMID: 9919092     DOI: 10.1177/105477389800700402

Source DB:  PubMed          Journal:  Clin Nurs Res        ISSN: 1054-7738            Impact factor:   2.075


  3 in total

1.  Preterm birth: a continuing challenge.

Authors:  Mary Lou Moore
Journal:  J Perinat Educ       Date:  2002

2.  Women's perspectives of the fetal fibronectin testing process: a qualitative descriptive study.

Authors:  Wendy E Peterson; Ann E Sprague; Jessica Reszel; Mark Walker; Deshayne B Fell; Sherry L Perkins; Sandra I Dunn; Moya Johnson
Journal:  BMC Pregnancy Childbirth       Date:  2014-06-04       Impact factor: 3.007

3.  Development and validation of the prenatal activity restriction stress questionnaire: a Rasch rating scale analysis.

Authors:  Hsiao-Ying Hung; Su-Pin Hung; Ying-Ju Chang
Journal:  BMC Pregnancy Childbirth       Date:  2020-10-31       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.